Home Clinical trials For patients Uterus IMGN151

IMGN151

A Phase 1, First-in-Human, Open-Label, Dose-Escalation and ExpansionStudy of IMGN151 (anti-FRα antibody-drug conjugate) in Adult Patients with Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers

Planned
Trial drug
IMGN151
Grade
High grade
Prior lines
1, 2, 3, 4, >4
Histology
Serous
Phase
I

Treatment

The treatment option in this study is IMGN151.
IMGN151 is given intravenously every 3 weeks.

Treatment duration

The treatment can continue until disease progression, unacceptable toxicities or until you decide to stop.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.